Skip to content

A Study of Chicory for Treatment of Osteoarthritis of the Hip or Knee

A Phase I Study of Chicory for Treatment of Osteoarthritis of the Hip or Knee

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01010919
Enrollment
Unknown
Registered
2009-11-10
Start date
Unknown
Completion date
Unknown
Last updated
2009-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Brief summary

Extracts of chicory root have anti-inflammatory properties in vitro and in animal models of arthritis. The primary objective of this investigator-initiated, Phase 1, placebo-controlled, double blind, dose-escalating trial is to determine the safety and tolerability of a proprietary bioactive extract of chicory root in patients with osteoarthritis (OA). Secondary objectives are to assess effects on the signs and symptoms of this disorder. Individuals greater than 50 years of age with OA of the hip or knee will be eligible for trial entry.

Interventions

DIETARY_SUPPLEMENTChicory root extract

Sponsors

University of Texas, Southwestern Medical Center at Dallas
CollaboratorOTHER
Phytomedics Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum

Inclusion criteria

1. Patients must be 50 years of age or older and may be of either gender. 2. Patients must have have an imaging-confirmed (radiograph or MRI) diagnosis of OA of the hip or knee. 3. Patients must not have taken a nonsteroidal anti-inflammatory medication for at least 7 days prior to the baseline visit (a single daily aspirin 325 mg or less is allowed throughout the study). 4. Patients must be able and willing to give informed consent.

Exclusion criteria

1. Any unstable comorbid medical condition that in the opinion of the investigator could interfere with the ability of the patient to complete the study. 2. Patients who are unable to ambulate and require a wheelchair due to the severity of the arthritis are excluded. Ambulatory aids such as canes and walkers are acceptable. 3. Patients requiring continuing therapy with nonsteroidal anti-inflammatory drugs are excluded. 4. Patients requiring any dose of glucocorticoids within the past 30 days are excluded.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026